Cue Biopharma Email Format
Biotechnology ResearchUnited States11-50 Employees
Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease and cancer. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.